The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer

Autor:	Xiaoling, Xu, Zhiyu, Huang, Lei, Zheng, Yun, Fan
Rok vydání:	2017
Předmět:	Antineoplastic Agents Immunological Lung Neoplasms Treatment Outcome Antineoplastic Combined Chemotherapy Protocols Programmed Cell Death 1 Receptor Humans CTLA-4 Antigen Molecular Targeted Therapy Publication Bias B7-H1 Antigen
Zdroj:	International journal of cancer. 142(11)
ISSN:	1097-0215
Popis:	Checkpoint inhibitors show promising efficacy in advanced lung cancer, especially in non-small-cell lung cancer (NSCLC). This meta-analysis was conducted to explore the therapeutic efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as first-line treatments for patients with advanced lung cancer. A systematic search was performed in databases for this system review and quantitative meta-analysis. Twelve trials were finally enrolled in the meta-analysis. Our analyses revealed that the combined overall response rate (ORR) and disease control rate (DCR) for immune checkpoint inhibitors combined with chemotherapy for the treatment of NSCLC were 47.0% (95% CI: 34.2%-60.2%) and 80.9% (95% CI: 69.4%-88.7%), respectively. The combined ORR and DCR for CTLA4 antibody combined with chemotherapy for the treatment of small-cell lung cancer (SCLC) were 65.4% (61.1%-69.5%) and 87.6% (84.5%-90.2%), respectively. The combined six-month progression-free survival rates (PFSRs
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::91f41fa382fe2dd9533507d136f2457e https://pubmed.ncbi.nlm.nih.gov/30715737 Zobrazit plný text záznamu Plný text